<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
AMENDMENT NO. 1
UNDER THE SECURITIES EXCHANGE ACT OF 1934*
Neoforma.com, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value per share
-------------------------------------------------------------------------------
(Title of Class of Securities)
640475 10 7
----------------------------------------------------
(CUSIP Number)
<TABLE>
<S> <C>
Harvey J. Wilson, Chairman and with a copy to:
Chief Executive Officer Hale and Dorr LLP
Eclipsys Corporation 11951 Freedom Drive
777 East Atlantic Avenue, Suite 200 Reston, Virginia 20190
Delray Beach, Florida 33483 Attention: Donald L. Toker
(561) 243-1440 (703) 654-7028
----------------------------------------------------------------------
Scott Decker, President and Chief with a copy to:
Executive Officer Hogan & Hartson L.L.P.
HEALTHvision, Inc. 555 Thirteenth Street, NW
6330 Commerce Drive, Suite 1000 Washington, DC 20004
Irving, Texas 75063 Attention: Christopher J. Hagan
(972) 819-4000 (202) 637-5771
----------------------------------------------------------------------
</TABLE>
------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
May 24, 2000
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Sections 240.13d-1(e), 240.13(d)-1(f) or
240.13d-1(g), check the following box [ ].
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
(Continued on following pages)
(Page 1 of 6 pages)
<PAGE> 2
SCHEDULE 13D
---------------------------- -----------------------
CUSIP No. 640475107 Page 2 of 6 Pages
---------------------------- -----------------------
<TABLE>
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Eclipsys Corporation
---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
---------------------------------------------------------------------
3 SEC USE ONLY
---------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
---------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
---------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
---------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH -------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
-------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
---------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
None
---------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
---------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
---------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
---------------------------------------------------------------------
</TABLE>
<PAGE> 3
SCHEDULE 13D
---------------------------- -----------------------
CUSIP No. 640475107 Page 3 of 6 Pages
---------------------------- -----------------------
<TABLE>
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
HEALTHvision, Inc.
---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
---------------------------------------------------------------------
3 SEC USE ONLY
---------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
---------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
---------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
---------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH -------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
-------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
---------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
None
---------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
---------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
---------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
---------------------------------------------------------------------
</TABLE>
<PAGE> 4
Page 4 of 6
This Amendment No. 1 amends the Statement on Schedule 13D filed with the
Securities and Exchange Commission on April 10, 2000 by Eclipsys Corporation
and HEALTHvision, Inc. (the "Statement"), relating to the Common Stock, $.001
par value per share, of Neoforma.com, Inc. Unless otherwise defined herein,
capitalized terms have the meanings assigned to them in the Statement.
ITEM 4. PURPOSE OF THE TRANSACTION
Item 4 is amended and supplemented as follows:
Eclipsys, HEALTHvision, Neoforma.com, Inc., NeoII Acquisition Corp.,
Novation LLC, VHA Inc., University HealthSystem Consortium, Healthcare
Purchasing Partners International, LLC entered into a Termination Agreement,
dated May 24, 2000 (the "Termination Agreement"). Pursuant to the Termination
Agreement, the Merger Agreement and the HEALTHvision Merger Agreement were
terminated. According to their terms the Voting Agreements terminated upon the
termination of the Merger Agreement and the HEALTHvision Merger Agreement. As a
result of the termination of the Voting Agreements, Eclipsys has ceased to hold
any interest in any shares of Neoforma's Common Stock which could be deemed to
make it the beneficial owner of such shares. In addition, as a result of the
termination of the Voting Agreements, HEALTHvision has ceased to hold any
interest in any shares of Neoforma's Common Stock which could be deemed to make
it the beneficial owner of such shares.
The description herein of the Termination Agreement is qualified in its
entirety by reference to the Termination Agreement, a copy of which was filed
by Eclipsys with the Securities and Exchange Commission on May 30, 2000, as an
exhibit to a Current Report on Form 8-K.
ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER
See Item 4 above, as amended.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDING OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Item 6 is amended in its entirety as follows:
Other than the Termination Agreement (see the response to Item 4 above),
to the knowledge of Eclipsys, there are no contracts, arrangements,
understandings or relationships among the persons named in Item 2 and between
such persons and any person with respect to any securities of Neoforma,
including but not limited to transfer or voting of any of the securities,
finder's fees, joint ventures, loan or option
<PAGE> 5
Page 5 of 6
arrangement, puts or calls, guarantees of profits, division of profits or loss,
or the giving or withholding of proxies.
Other than the Termination Agreement (see the response to Item 4 above),
to the knowledge of HEALTHvision, there are no contracts, arrangements,
understandings or relationships among the persons named in Item 2 and between
such persons and any person with respect to any securities of Neoforma,
including but not limited to transfer or voting of any of the securities,
finder's fees, joint ventures, loan or option arrangement, puts or calls,
guarantees of profits, division of profits or loss, or the giving or
withholding of proxies.
<PAGE> 6
Page 6 of 6
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Amendment No. 1 to Schedule 13D
is true, complete and correct.
Eclipsys Corporation
By: /s/ Gregory L. Wilson
---------------------
Name: Gregory L. Wilson
Title: Chief Financial Officer
HEALTHvision, Inc.
By: /s/ Randall D. Kurtz
---------------------------------
Name: Randall D. Kurtz
Title:Chief Financial Officer
